Related Experiment Video
Updated: Jun 12, 2026

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice
Published on: July 19, 2019
Rapamycin-induced posterior reversible encephalopathy in a kidney transplantation patient
Wei Qin1, Chun Yu Tan, Xiaoqi Huang
1Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, China.
Background:
Posterior reversible encephalopathy syndrome (PRES) is characterized by abnormalities in cerebral white matter and neurologic symptoms. It can be caused by immunosuppressive drugs or autoimmune diseases. We describe a case of PRES in a kidney transplantation patient treated with rapamycin.
Case:
A 24-year-old woman, who received kidney transplantation 8 years ago, presented hypertension (220/120 mmHg), blindness, paralysis of left extremities, vomiting, convulsions and unconsciousness after rapamycin treatment. Magnetic resonance imaging (MRI) showed brain lesions suggestive of PRES. Rapamycin was withdrawn, and repeated MRI indicated progressive resolution within 2 months.
Conclusion:
Although neurotoxicity of rapamycin is relatively low, it can induce PRES in kidney transplantation patients.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Kidney Transplant III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention

